| DC10609 |
BMS-986158
Featured
|
BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins. |
|
| DC12221 |
BRD 4354
Featured
|
BRD 4354 is a moderately potent inhibitor of HDAC5 and HDAC9, with IC50s of 0.85 and 1.88 μM, respectively. |
|
| DC7674 |
BRD4770
Featured
|
BRD4770 is a selective inhibitor of the histone methyltransferase G9a. |
|
| DC7936 |
BRD73954
Featured
|
BRD-73954 is a biochemical inhibitor histone deacetylase cancer histone modification epigenetics gene regulation small molecule HDAC6 HDAC8. |
|
| DC7658 |
C646
Featured
|
C646 is an inhibitor for histone acetyltransferase, and inhibits p300 with a Ki of 400 nM. Preferentially selective for p300 versus other acetyltransferases. |
|
| DC10744 |
Cambinol
Featured
|
Cambinol is a SIRT1 and SIRT2 inhibitor with IC50 values of 56 and 59 μM, respectively. |
|
| DC10579 |
CAY 10602
Featured
|
CAY10602 is a SIRT1 activator. |
|
| DC8036 |
CAY10603
Featured
|
CAY10603 is a potent and selective inhibitor of HDAC6 with IC50 of 2 pM, as compared with 271, 252, 0.42, 6851, and 90.7 nM for HDAC1, 2, 3, 8, and 10, respectively. |
|
| DC7738 |
CAY10683(Santacruzamate A)
Featured
|
CAY10683 is a potent and selective HDAC inhibitor with IC50 of 119 pM for HDAC2, >3600-fold selectivity over other HDACs. |
|
| DC10944 |
CBB3001 |
CBB3001 (CBB-3001) is a novel potent, selective histone demethylase LSD1 inhibitor with IC50 of 21.25 uM. |
|
| DC9923 |
CeMMEC1
Featured
|
CeMMEC1 is a novel potent inhibitor of the second bromodomain of TAF1, binding neither the first nor the second bromodomain of BRD4. |
|
| DC7978 |
Tucidinostat(Chidamide)
Featured
|
Chidamide is a class I HDAC inhibitor with IC50s of 95/160/67/733 nM for HDAC1/2/3/8; also inhibits HDAC10/11(IC50=78/432 nM); no inhibition on HDAC4/5/7/9/6(IC50>30 uM). |
|
| DC2060 |
CI994 (Tacedinaline)
Featured
|
CI994 (Tacedinaline) is an anti-cancer drug which inhibits HDAC1 with IC50 of 0.57 μM. |
|
| DC10795 |
CM-272
Featured
|
CM-272 is a first-in-class reversible dual small molecule inhibitor against G9a and DNMTs in hematological malignancies. |
|
| DC12098 |
Corin
Featured
|
Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a Ki(inact) of 110 nM for LSD1 and an IC50 of 147 nM for HDAC1. |
|
| DC5046 |
CPI203 (CPI-203)
Featured
|
CPI203 is a novel potent, selective and cell permeable inhibitor of the bromodomain and extra terminal (BET) family protein BRD4 with an IC50 of ~37 nM (BRD4 α-screen assay). |
|
| DC8619 |
CPI-268456
Featured
|
CPI-268456 is a potential BET bromodomain inhibitor. |
|
| DC9858 |
CPI-455
Featured
|
CPI-455 is a specific, pan-KDM5 inhibitor with an IC50 of 10 nM for KDM5A. CPI-455 mediates KDM5 inhibition, elevates global levels of H3K4me3, and decreases the number of drug-tolerant persister cancer cells in multiple cancer cell line models treated with standard chemotherapy or targeted agents. |
|
| DC10477 |
CPI-637
Featured
|
CPI-637 is a potent and selective CBP/EP300 bromodomains inhibitor with IC50 of 0.03±0.01μM and 11.0±0.6 μM for CBP/EP300 and BRD4, respectively. |
|
| DC10970 |
CPTH2 |
CPTH2 is a specific histone acetyltransferase inhibitor modulating Gcn5 network in vitro and in vivo, inhibits H3 acetylation and induces cell-cycle perturbation and apoptosis in U-937 cells. |
|
| DC10969 |
CPTH6 hydrobromide |
CPTH6 hydrobromide is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor. |
|
| DC10968 |
CPTH6 |
CPTH6 is a thiazole derivative that can reduce histone acetylation and histone acetyltransferase (HAT) activity in human leukemia cells, CPTH6 is a specific Gcn5/pCAF inhibitor. |
|
| DC7544 |
CUDC-101
Featured
|
CUDC-101 is a potent multi-targeted inhibitor against HDAC, EGFR and HER2 with IC50 of 4.4 nM, 2.4 nM, and 15.7 nM, and inhibits class I/II HDACs, but not class III, Sir-type HDACs. Phase 1. |
|
| DC9925 |
CXD101(AZD-9468)
Featured
|
CXD101(AZD-9468) is a novel histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. |
|
| DC7182 |
Dacinostat (NVP-LAQ824, LAQ824)
Featured
|
Dacinostat (NVP-LAQ824, LAQ824) is a highly potent HDAC inhibitor with IC50 of 32 nM. |
|
| DC10413 |
DDP-38003 dihydrochloride |
DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC50 of 84 nM. |
|
| DC8385 |
Disodium (R)-2-Hydroxyglutarate
Featured
|
Disodium (R)-2-Hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases with Ki of 0.628 mM. |
|
| DC8350 |
Droxinostat
Featured
|
Droxinostat is a selective HDAC3, HDAC6 and HDAC8 inhibitor. |
|
| DC11213 |
E1231
Featured
|
E1231 (E-1231) is a small molecule SIRT1 activator with EC50 of 0.83 uM, interactes with recombinant human SIRT1 protein and deacetylated liver X receptor-alpha (LXRα). |
|
| DC11477 |
EBI-2511
Featured
|
EBI-2511 is a highly potent and orally active EZH2 inhibitor for the treatment of Non-Hodgkin’s Lymphoma. |
.gif)
|
